1. In Vivo

BTG Has The Firepower For Its Next Steps In Interventional Med

 
• By Ashley Yeo

UK-listed BTG PLC shares the UK life science industry's concerns about long-term negative fallout from Brexit, but it finds itself in a relatively comfortable position. The acquisitive interventional medicines company says it has plenty of firepower for more M&A.

Among those watching the slow motion tumble in the value of sterling as the UK government feels its way through the economic darkness it has created for itself, UK-listed BTG PLC finds itself in a relatively comfortable position. The acquisitive interventional medicines (IM) company is currently recording 90% of its sales in US dollars, and has moved its full-year 2016–17 sales guidance up by £25 million ($31 million), simply as a result of the Brexit-induced currency translation effect.

BTG's guidance was originally set at $1.45, which it then lowered to $1.30 and most recently set at $1.25. The...

More from Growth

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.